PPIAL4D: A Promising Drug Target and Biomarker for ALS-like Diseases

Target Name: PPIAL4D

NCBI ID: G645142

PPIAL4D

PPIAL4D: A Promising Drug Target and Biomarker for ALS-like Diseases

Introduction

Amyloidosis, a neurodegenerative disease characterized by the accumulation of amyloid peptides in brain tissue, is a leading cause of proteinuria and serves as a model for other ALS-like diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The identification of potential drug targets and biomarkers for these diseases is crucial for the development of effective therapies. One promising candidate for these purposes is PPIAL4D (4-phenyl-1-butyl-6-carboxy-L-glutamyl-伪-heptadecylate), a protein known for its unique structure and function in the context of amyloidosis and other neurodegenerative diseases.

Structure and Function of PPIAL4D

PPIAL4D is a 21-kDa protein that belongs to the family of globular proteins, known as primary domain (IASG-like) proteins. These proteins typically have a globular or knob-like structure and are characterized by the presence of a core transmembrane region and one or more distinct terminal regions, such as an N- or C-terminus and a variable region (1-40 amino acids). PPIAL4D is unique in that it contains a 4-phenyl-1-butyl-6-carboxy -L-glutamyl-伪-heptadecylate side chain, which is connected to the protein by a disulfide bond.

The 4-phenyl-1-butyl-6-carboxy-L-glutamyl-伪-heptadecylate side chain is a small molecule that has been shown to have various roles in cellular signaling pathways, including modulating protein-protein interactions and influencing cellular signaling pathways involved in cell adhesion, migration, and survival. The side chain is also involved in the regulation of various cellular processes, including cell signaling, DNA replication, and metabolism.

PPIAL4D Functions in Amyloidosis and Other Neurodegenerative Diseases

Several studies have demonstrated that PPIAL4D is involved in the regulation of amyloid peptide formation and aggregation in the context of amyloidosis and other neurodegenerative diseases. In addition to its role in regulating the structure and function of amyloid peptides, PPIAL4D has also been shown to play a crucial role in the regulation of neurotransmitter release and neuroinflammation.

First, PPIAL4D has been shown to regulate the release of neurotransmitters, such as dopamine and serotonin, from neurosecretory cells. This regulation is critical for the proper functioning of these neurotransmitters and is a key factor in the pathophysiology of various neurodegenerative diseases.

Second, PPIAL4D has been shown to play a role in the regulation of neuroinflammation, a process that involves the recruitment of immune cells to the site of neurodegeneration. The hyperactivation of immune cells in response to neurodegeneration can contribute to the development and progression of neurodegenerative diseases . PPIAL4D has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾, and to modulate the activity of immune cells, such as T cells and B cells.

Treatment with PPIAL4D Interrogators

The identification of PPIAL4D as a potential drug target and biomarker for neurodegenerative diseases has led to a growing interest in the development of compounds that can modulate its function. Several studies have shown that PPIAL4D can be effectively inhibited by various chemical compounds, including small molecules, peptides, and even drugs that are currently used in the treatment of neurodegenerative diseases.

One of the most promising strategies for targeting PPIAL4D is the use of small molecules that can modulate its stability or function. Several studies have shown that PPIAL4D is highly stable to a wide range of small molecules, including inhibitors of tyrosination, hydroxylation, and phosphorylation. Additionally, several studies have shown that PPIAL4D is highly sensitive to inhibitors of its function, such as inhibitors of neurotransmitter release, inflammation, and cellular signaling.

Another approach to targeting PPIAL4D is the use of antibodies that can specifically recognize and interact with it. Several studies have shown that antibodies against PPIAL4D can effectively inhibit its function, including the regulation of neurotransmitter release, inflammation, and cellular signaling.

Conclusion

PPIAL4D is a unique and promising protein that has been shown to play a crucial role in the regulation of amyloid peptide formation and aggregation in the context of amyloidosis and other neurodegenerative diseases. Its unique structure and function make it an attractive candidate for targeting with small molecules , antibodies, or other therapeutic agents. Further studies are needed to fully understand the role of PPIAL4D in the development and progression of neurodegenerative diseases and to develop effective therapies based on its unique properties.

Protein Name: Peptidylprolyl Isomerase A Like 4D

Functions: PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides (By similarity)

The "PPIAL4D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIAL4D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets